is are required to respond to a collection of information unless it displays a valid OMB control number. TERMINAL DISCLAIMER TO OBVIATE A PROVISIONAL DOUBLE PATENTING Docket Number (Optional) REJECTION OVER A PENDING "REFERENCE" APPLICATION 17359CON2CIP1CIP1 (BOT)

In re Application of: Stephen Donovan
Application No.: 10/752,871
Filed: 01-06-2004
For: Intravitreal Botulinum Toxin Implant
The owner* .ALESGAN_INC. of .100 percent interest in the instant application hereby disastion hereby disastion in the property of the statutory term of any patent generate on the instants application which would extend beyond the expiration date of the full statutory term of any patent generate on the instant application which would extend beyond the expiration date of the full statutory term of any patent generated on pending reference Application Nursery .10445-142 on .52-32-003 as so with term is defined in S.U.S.C. 154 and 173, and as the term of any patent granted on said reference application may be shortened by any terminal disclaimer filled prior to the grant of any patent on the pending reference application. The owner hereby agrees that any patents og parted on the instant application stant applica
In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the fall statutory term as defined in \$5 U.S.C. 15 and 173 of any patent granted or side reference application, "as the term of any patent granted on said reference application," as the term of any patent granted on said reference application may be shortened by any terminal disclaimer filed prior to the grant of any patent or the pending reference application." In the event that any such patent; granted on the pending reference application, as the strength of the part of the patent preference application expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.21, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to the grant.
Check either box 1 or 2 below, if appropriate.
 For submissions on behalf of a business/organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the business/organization.
I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and bellef are believed to be true, and further that these statements were made with the knowledge that willing false statement that like so made are punishable by fine or imprisonment, or both, under Section 1001 of Tale 18 of the United States Code and that such willful false statements may loperatize the validity of the application or any patern issued thereon.
2. The undersigned is an attorney or agent of record. Reg. No. 33,433
/Stephen Donovan/ 7-30-08
Signature Date
Stephen Donovan Typed or printed name
"
(714) 246-4026 Telephone Number
▼ Terminal disclaimer fee under 37 CFR 1.20(d) is included.
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

"Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner).